New drug combo aims to shrink breast tumors before surgery
NCT ID NCT07410559
First seen Feb 15, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests whether a combination of two drugs (imlunestrant and abemaciclib) given before surgery can shrink tumors in people with ER-positive, HER2-negative breast cancer. The treatment plan is adjusted based on a marker called Ki67 measured after two weeks. About 189 women aged 18-75 with early-stage breast cancer will take part. The goal is to see if this approach improves tumor response and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.